Volume 5, Issue 5
Editorialp. 433–435
Adaptive designs for clinical trials with multiple endpoints
Author(s): Geraldine Rauch, Meinhard Kieser
Editorialp. 437–439
The importance of budgeting in clinical trials and how a budget can prevent billing errors
Author(s): Mitchell Appleson
Research Updatep. 441–445
PEARL translational network: an infrastructure for person-centricity and improved clinical outcomes
Author(s): Frederick A Curro, Dennis A Robbins, Frederick Naftolin, Ashley Grill, Don Vena, Louis Terracio & Van P Thompson
Special Reportp. 447–456
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Author(s): Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Clinical Trail Perspectivep. 457–475
Ophthalmic pharmaceutical clinical trials: design considerations
Author(s): Paul Varner
Clinical Trail Perspectivep. 477–490
Ophthalmic pharmaceutical clinical trials: interpretation
Author(s): Paul Varner
Clinical Trail Methodologyp. 491–499
An evidence-based approach to conducting clinical trial feasibility assessments
Author(s): Otis Johnson
Clinical Trail Outcomesp. 501–507
Parathyroid hormone replacement in hypoparathyroidism
Author(s): Sharon H Chou & Tamara Vokes
Clinical Trail Outcomesp. 509–517
Uveitic macular edema: a stepladder treatment paradigm
Author(s): Janine M Preble, Charles Stephen Foster
Clinical Trail Outcomesp. 519–528
New treatments for neurogenic detrusor overactivity
Author(s): Gabriele Gaziev, Valerio Iacovelli, Luca Topazio, Daniele Bianchi & Enrico Finazzi Agro
